Page last updated: 2024-10-15

blz-100

Description

tozuleristide: a tumor contrast agent that consists of 36-amino-acid peptide derived from the scorpion venom chlorotoxin conjuated to indocyanine green [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID145994618
MeSH IDM000614313

Synonyms (3)

Synonym
tozuleristide
blz-100
DB15375

Toxicity

ExcerptReference
" No dose-limiting toxicity was observed, and no reported adverse events were considered related to tozuleristide."( Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas.
Black, K; Butte, P; Byrnes-Blake, KA; Hansen, SJ; Ishak, L; Kittle, DS; Lin, LL; Mamelak, AN; Miller, DM; Morrison, B; Nufer, KL; Parrish-Novak, J; Patil, CG; Perry, J; Pham, K; Prow, T; Walker, DG; Yamada, M, 2019
)

Pharmacokinetics

ExcerptReference
" Fluorescence images of tumor and cavity in Situ before and after resection and of excised tissue ex Vivo were acquired, along with safety and pharmacokinetic measures."( Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas.
Black, K; Butte, P; Byrnes-Blake, KA; Hansen, SJ; Ishak, L; Kittle, DS; Lin, LL; Mamelak, AN; Miller, DM; Morrison, B; Nufer, KL; Parrish-Novak, J; Patil, CG; Perry, J; Pham, K; Prow, T; Walker, DG; Yamada, M, 2019
)
" At doses of 9 mg and above, the terminal serum half-life for tozuleristide was approximately 30 min."( Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas.
Black, K; Butte, P; Byrnes-Blake, KA; Hansen, SJ; Ishak, L; Kittle, DS; Lin, LL; Mamelak, AN; Miller, DM; Morrison, B; Nufer, KL; Parrish-Novak, J; Patil, CG; Perry, J; Pham, K; Prow, T; Walker, DG; Yamada, M, 2019
)

Dosage Studied

ExcerptReference
" In high-grade tumors, signal intensity increased with increased dose levels of tozuleristide, regardless of the time of dosing relative to surgery."( Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas.
Black, K; Butte, P; Byrnes-Blake, KA; Hansen, SJ; Ishak, L; Kittle, DS; Lin, LL; Mamelak, AN; Miller, DM; Morrison, B; Nufer, KL; Parrish-Novak, J; Patil, CG; Perry, J; Pham, K; Prow, T; Walker, DG; Yamada, M, 2019
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (14.29%)0.25%
Other4 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]